Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267218 | 0.76 | MAPT (0.41) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL14093776 | 0.74 | KDM4E (0.42) | MAPTLMNAKMT2AMEN1KDM4E | |
| SCHEMBL4989105 | 0.72 | SMN1; SMN2 (0.50) | MAPTLMNAHTTHASPINKDM4E | |
| SCHEMBL4989273 | 0.71 | KDM4E (0.47) | MAPTLMNAHASPINKMT2AMEN1 | |
| SCHEMBL282648 | 0.66 | TSHR (0.56) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL8809521 | 0.65 | MAPT (0.40) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL4829285 | 0.65 | MAPT (0.38) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL8811728 | 0.65 | ALDH1A1 (0.44) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL4982583 | 0.64 | RXFP1 (0.39) | MAPTLMNAKMT2AMEN1KDM4E | |
| SCHEMBL8814038 | 0.62 | LMNA (0.43) | MAPTLMNAHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414066-B2 | Amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-7393866-B2 | Amide compounds and medications containing the same | KOWA COMPANY, LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| EP-0979823-B1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-6849647-B1 | Amide compounds and medications containing the same technical field | KOWA COMPANY, LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| EP-0987254-B1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-0987254-A1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0979823-A1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | ACAT2, SULT2A1, ACAT1 | MAPT 1444/4885LMNA 4703/4885HTT 1812/4885 |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | ACAT2, SULT2A1, ACAT1 | MAPT 930/4885LMNA 4629/4885HTT 2029/4885 |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | MAPT 1164/4885LMNA 4085/4885HTT 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.